REGENXBIO Inc — Quarterly Cash Flow (NASDAQ:RGNX) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics

Quarterly Annual

Total assets 465.99 M490.93 M581.03 M525.2 M453.03 M Total liabilities 206.34 M216.73 M367.35 M363.75 M350.3 M Total equity 259.65 M274.2 M213.68 M161.45 M102.73 M Total liabilities & shareholders' equities 465.99 M490.93 M581.03 M525.2 M453.03 M Total debt ————— Net debt —————

뉴스

Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval

OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development

Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data

OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch

파콜라 스티브, 리젠엑스바이오 CMO, RGNX 주식 5.3만 달러 상당 매도

Pakola Steve, Regenxbio CMO, sells $53k in RGNX stock

REGENXBIO Inc. (RGNX) Presents at 2026 MDA Clinical & Scientific Conference - Slideshow (NASDAQ:RGNX) 2026-03-12

Stifel, Regenxbio ’듀켄’ 임상 데이터에 ’매수’ 등급 유지

Stifel reiterates Regenxbio stock rating on Duchenne trial data

듀셴형 유전병 치료제, 리젠엑스바이오 긍정적 중간 데이터 발표

Regenxbio reports positive interim data for Duchenne gene therapy

Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals - Regenxbio (NASDAQ:RGNX)